Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
- Status
- WITHDRAWN
- Phase
- PHASE4
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
- Status
- COMPLETED
- Phase
- PHASE3
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
- Status
- WITHDRAWN
- Phase
- PHASE2
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
- Status
- COMPLETED
- Phase
- N/A
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
- Status
- COMPLETED
- Phase
- PHASE2